SecBot SecBot
Biotech Drug Report Generated Jul 14, 2026

darlifarnib

KURA·Kura Oncology, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Likely 4-6+ years if successful; still in Phase 1 with registrational Phase 3 planned for 2028 at the earliest
Why 4/10
Darlifarnib is a Phase 1 asset with no PDUFA or pivotal readout in the next ~12 months. The next near-term catalyst is an oral presentation of updated Phase 1a long-term follow-up data at KCRS 2026 (July 24, 2026), which is incremental data from an already-disclosed dose-escalation cohort. Kura has an approved product (ziftomenib) and a broader pipeline, so darlifarnib is not a single-asset binary. ImpactScore of 4 reflects an early-stage program where the next catalyst is a conference presentation rather than a registration-quality binary.
Actionable Insight NEUTRAL

Investors should watch the KCRS 2026 oral presentation on July 24 and the virtual investor call on July 27 for updated long-term Phase 1a durability data in ccRCC. The program is too early for binary positioning, the real value inflection points (Phase 1b randomization data, Phase 3 start in 2028, and the daraxonrasib combo entering the clinic in early 2027) are 12+ months away. KURA is a multi-asset company with an approved product, so darlifarnib is one of several value drivers.

Price Chart

Loading chart...

Executive Summary

Darlifarnib (KO-2806) is Kura Oncology's next-generation, oral farnesyl transferase inhibitor in Phase 1 clinical development. It is designed to be used in combination with other targeted therapies to overcome drug resistance in KRAS-mutant and other solid tumors. Early Phase 1a data have shown encouraging objective response rates, 67% in pancreatic cancer and 50% in NSCLC when combined with the KRAS G12C inhibitor adagrasib, but these are small, early-stage numbers. Kura is pursuing a broad platform strategy, with the first planned combination (darlifarnib + daraxonrasib in pancreatic cancer) expected to enter Phase 1a in early 2027. The drug is still early-stage and far from commercialization, but Kura has a strong balance sheet ($667M cash + ~$180M in collaboration payments), an approved product (ziftomenib for AML) already generating revenue, and broad institutional support. The stock carries a Strong Buy consensus with a mean price target of ~$31, but with a high short-interest ratio (~46-48% short volume) suggesting significant bearish positioning as well.

How It Works

Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI), an oral pill that blocks an enzyme called farnesyl transferase. This prevents certain cancer-driving proteins (RAS family and RHEB) from attaching to cell membranes, where they would normally turn on growth signals. Importantly, it selectively shuts down the mTORC1 growth pathway (a common resistance mechanism) while leaving mTORC2 alone to limit side effects. In plain terms: it cuts off a key backup pathway that cancer cells use to evade other targeted drugs, making it a potential combination partner for KRAS inhibitors, VEGF inhibitors, and PI3Kα inhibitors.

Trial Status

Darlifarnib is being evaluated in the FIT-001 Phase 1a/1b first-in-human trial (NCT06026410) in three dose-escalation arms: monotherapy, plus cabozantinib (in ccRCC), and plus adagrasib (in KRAS G12C tumors). Preliminary Phase 1a data was presented at ASCO 2026 showing promising response rates in pancreatic cancer (67% ORR), NSCLC (50% ORR), and CRC (29% ORR) in combination with adagrasib. Updated long-term Phase 1a data for the cabozantinib combo in ccRCC is being presented at KCRS 2026. A randomized Phase 1b dose-optimization portion is enrolling in the U.S. and EU, designed to inform selection of a recommended Phase 3 dose for a registrational study planned for 2028.

The Two-Sided Case

▲ Bull Case5
Early Phase 1a data show compelling efficacy: darlifarnib + adagrasib achieved 67% confirmed ORR in pancreatic cancer (historically hard-to-treat), 50% in NSCLC, and 29% in KRASi-naïve CRC, with tumor shrinkage in 77% of evaluable patients (source: ASCO 2026 presentation via BioSpace press release).
The FTI mechanism targets mTORC1-mediated resistance, a well-validated pathway; preclinical data from Cancer Research (May 2026) showed darlifarnib added to RAS inhibitors led to rapid and durable tumor regression in resistant models (source: AACR journal publication).
Kura has a strong balance sheet ($667.2M cash as of Q4 2025 + ~$180M in anticipated collaboration payments) funding operations into Q4 2027, providing years of runway to develop darlifarnib without near-term dilution risk (source: Kura Q4 2025 earnings press release, GlobeNewswire).
Broad institutional accumulation in Q1 2026, Bank of America added 46.1%, Walleye Capital doubled its position (+5,811%), Dimensional Fund Advisors added 32.3%, signaling smart-money interest in the broader Kura story.
Analyst consensus is Strong Buy with mean price target of $31.17 (~185% upside from ~$11) across 12 analysts; HC Wainwright maintained a $40 target, Barclays an $28 Overweight, Wedbush $38 Outperform.
▼ Bear Case5
Darlifarnib is still only in Phase 1, no randomized controlled data, no Phase 2/3 results. The impressive 67% ORR in pancreatic cancer comes from small patient numbers (single digits) in an early dose-escalation cohort, not a registrational trial (source: ASCO 2026 abstract #3078).
The registrational Phase 3 study is not planned until 2028, meaning FDA approval (if any) is 4-6+ years away. The next pivotal catalyst, Phase 1b randomized data, has no announced readout date, leaving a long data gap (source: Kura press releases).
Short interest is elevated, the 14-day average short volume ratio was ~48% as of mid-July 2026, with a z-score of +1.84 on July 13 signaling elevated bearish positioning.
Insider selling: the Chief Medical Officer sold 84,929 shares at ~$9.82 on June 18, 2026 under a 10b5-1 plan, a sizable transaction ($834K) (source: SEC Form 4 filing).
The FTI drug class has a mixed history, earlier FTIs (tipifarnib, lonafarnib) failed to meet expectations in pivotal trials despite promising early signals, raising execution risk for a next-generation FTI even with a refined mechanism (source: historical drug development context).

Upcoming Catalysts

  • KCRS 2026 oral presentation of long-term Phase 1a follow-up data for darlifarnib + cabozantinib in ccRCC, July 24, 2026 (Boston)
  • Virtual investor event following KCRS, July 27, 2026
  • Randomized Phase 1b dose-optimization data for darlifarnib + cabozantinib vs cabozantinib alone in ccRCC (no date announced; currently enrolling)
  • First planned platform combination, darlifarnib + daraxonrasib entering Phase 1a in KRAS-mutant pancreatic cancer in early 2027
  • Registrational Phase 3 study selection and initiation planned for 2028

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Kura Oncology, Inc. Press Release KURA ·Originating report

Sources · 9

Hover a chip for the title
1 biospace.com2 quiverquant.com3 ascopubs.org4 biospace.com5 cancer.gov6 aacrjournals.org7 biospace.com8 kuraoncology.com9 clinicaltrials.gov